Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer
Phase 2
Completed
- Conditions
- Gastric Cancer
- Interventions
- Registration Number
- NCT04338438
- Lead Sponsor
- Beijing Friendship Hospital
- Brief Summary
This is a single-arm, interventional study aimed to observe the efficacy and safety of Apatinib combined with S-1 for patients with advanced gastric cancer refractory to oxaliplatin plus capecitabine combination therapy
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 37
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Apatinib Mesylate tablets combined with S-1 capsules Apatinib Mesylate tablets combined with S-1 capsules single arm trial: apatinib 500 mg once daily, across entire cycle and S-1 60 mg twice daily, on the first 14 days of a 21-day cycle. Medication was continued until the disease progression, withdrawal requirement, or intolerable adverse events
- Primary Outcome Measures
Name Time Method median progression-free survival(mPFS) 2 years The median duration of time between when a patient with oncological disease receives treatment and when the disease progresses or death due to any cause occurs.
median overall survival(mOS） 2 years The median time from treatment to the last follow-up or death.
- Secondary Outcome Measures
Name Time Method objective response rate(ORR) 2 years The rate of patients achieved complete response or partial response
disease control rate(DCR) DCR 2 years The rate of patients achieved complete response or partial response or solid disease.